The European Commission has granted marketing authorization for Novo Nordisk’s Wegovy pill for people with obesity or who are overweight. The approval comes as Novo’s weight-loss rival, Eli Lilly, awaits European clearance for its oral GLP-1 drug, Foundayo.
Source: FiercePharma
